Introduction: CML in the imatinib era.
Hehlmann
R
R
Medizinische Fakultäet Mannheim der Universitäet Heidelberg, Pettenkoferstr. 22, 68169 Mannheim, Germany. matthias.dumke@med3.ma.uni-heidelberg.de
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D019496:Cancer Vaccines; D016503:Drug Delivery Systems; D006801:Humans; D000068877:Imatinib Mesylate; D007167:Immunotherapy; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000628:therapy; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001549:Benzamides; D019496:Cancer Vaccines; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate